Clovis Oncology (NASDAQ:CLVS) – Equities research analysts at Leerink Swann issued their Q3 2018 earnings per share (EPS) estimates for shares of Clovis Oncology in a research report issued on Monday, September 24th. Leerink Swann analyst A. Berens forecasts that the biopharmaceutical company will post earnings per share of ($1.52) for the quarter. Leerink Swann has a “Market Perform” rating and a $30.00 price target on the stock. Leerink Swann also issued estimates for Clovis Oncology’s Q4 2018 earnings at ($1.51) EPS, FY2018 earnings at ($6.51) EPS, FY2019 earnings at ($4.77) EPS, FY2020 earnings at ($1.50) EPS, FY2021 earnings at $1.10 EPS and FY2022 earnings at $2.65 EPS.
Several other equities analysts have also issued reports on the stock. JPMorgan Chase & Co. reissued a “buy” rating and set a $71.00 price objective on shares of Clovis Oncology in a report on Friday, September 21st. Guggenheim assumed coverage on shares of Clovis Oncology in a report on Monday, September 17th. They set a “buy” rating on the stock. Cann assumed coverage on shares of Clovis Oncology in a report on Wednesday, August 8th. They set a “hold” rating on the stock. ValuEngine raised shares of Clovis Oncology from a “strong sell” rating to a “sell” rating in a report on Thursday, August 2nd. Finally, Gabelli reissued a “buy” rating on shares of Clovis Oncology in a report on Monday, July 16th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $73.41.
Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Wednesday, August 1st. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.56). The business had revenue of $23.76 million for the quarter, compared to analysts’ expectations of $22.44 million. Clovis Oncology had a negative net margin of 382.83% and a negative return on equity of 94.28%. The business’s quarterly revenue was up 62.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.29) earnings per share.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Palo Alto Investors LP grew its holdings in Clovis Oncology by 16.2% in the first quarter. Palo Alto Investors LP now owns 3,955,660 shares of the biopharmaceutical company’s stock worth $208,859,000 after purchasing an additional 552,879 shares during the last quarter. Redmile Group LLC purchased a new position in Clovis Oncology in the second quarter worth $79,964,000. Carmignac Gestion grew its holdings in Clovis Oncology by 14.3% in the first quarter. Carmignac Gestion now owns 1,509,540 shares of the biopharmaceutical company’s stock worth $79,704,000 after purchasing an additional 188,676 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in Clovis Oncology by 1.0% in the first quarter. Point72 Asset Management L.P. now owns 1,155,937 shares of the biopharmaceutical company’s stock worth $61,033,000 after purchasing an additional 11,937 shares during the last quarter. Finally, Macquarie Group Ltd. grew its holdings in Clovis Oncology by 12.3% in the second quarter. Macquarie Group Ltd. now owns 691,459 shares of the biopharmaceutical company’s stock worth $31,441,000 after purchasing an additional 75,589 shares during the last quarter.
Clovis Oncology Company Profile
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Read More: Why is the conference call important?
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.